NcoI polymorphism within the promoter/enhancer region of TNFa and the first intron of TNFb encoding gene was analysed in 70 patients with haematological malignancies transplanted from HLA-identical sibling donors. The control group was composed of 130 healthy individuals. We showed that patients heterozygous for one or both TNF genes suffered more frequently from severe (grades III-IV) toxic complications than those carrying the other TNF genotypes (TNFA*1,2: 9/10 vs 30/60, Po0.05; TNFB*1,2: 20/26 vs 19/44, Po0.01; TNFA*1,2 TNFB*1,2: 9/9 vs 30/61, Po0.005). Conversely, patients having TNFB*2,2 less frequently presented with severe toxic lesions (17/39 vs 22/31, Po0.05). Additional analyses showed that TNFA*1,2, independent of the TNFB genotype composition, influenced the manifestation of grades III-IV toxic lesions, while TNFB*2,2 and TNFA*1,1 in combined association played a protective role. Logistic regression analysis confirmed the association of recipient TNFA*1,2 genotype with severe toxic complications, in addition to aggressive myeloablative conditioning regimen and female to male transplantation. No relation was found between TNF polymorphic features and aGvHD incidence by either uni-or multivariable analyses. Bone Marrow Transplantation (2003) 32, 617-622. doi:10.1038/sj.bmt.1704200 Keywords: TNF a; TNF b; NcoI polymorphism; GvHD; toxicity; HSCT Transplantation of haematopoietic stem cells (HSCT) is a curative treatment of many haematological disorders. However, although significant advances have been made in conditioning regimens, HSCT is associated with a number of post-transplant complications, including generation of toxic lesions and graft-versus-host-disease (GvHD). Both T cells and cytokines are the major effectors in GvHD. 1, 2 The disease occurs even in the recipients transplanted from HLA-identical sibling donors, affecting up to 40-50% of patients. The high occurrence in these patients has been largely attributed to minor histocompatibility differences between the donor and recipient 3 and the presence of particular HLA specificities in donor-patient pairs. 4, 5 In addition, more recently non-HLA genes coding for cytokines involved in the pathogenesis/control of the disease have been implicated. [6] [7] [8] TNFa and TNFb are proinflammatory cytokines with a number of biological activities including the mediation of inflammatory responses. 9 Proinflammatory cytokines, especially TNFa, are involved in both the induction and effector phase of aGvHD. 1, 2 This cytokine is released pretransplant as a result of irradiation and cytotoxic preconditioning regimens. Indeed, TNFa serum level during the preconditioning treatment has been shown to correlate with severe complications, the manifestation of aGvHD and mortality after HSCT. 10 The role of TNFa as a mediator of GvHD has also been documented by in vitro skin explant assay. [11] [12] [13] TNFb is much less elucidated in GvHD. However, TNFB allelic specificities have been found to affect the outcome of sepsis. 14 Stuber et al 14 documented that the survival of TNFB*1,2 heterozygous patients with sepsis was significantly higher than that of TNFB*2 homozygotes. Moreover, both TNFA and TNFB polymorphic features have been shown to be associated with TNFa generation potential. [15] [16] [17] [18] Thus, the influence of TNFA and TNFB polymorphism may be functionally significant in diseases in which the pathomechanism includes TNFa production. Middleton et al 6 and Kogler et al 19 have documented associations between the presence of the TNFd3 homozygous allele and the manifestation of severe aGvHD in both bone marrow and cord blood transplant recipients, respectively.
In the present study, we focused on the NcoI polymorphic features of the promoter region of TNFA gene and the first intron of TNFB gene, in patients who had undergone allogeneic HLA-identical HSCT. The TNF polymorphism results were correlated with clinical outcome, the incidence and severity of toxic complications and aGvHD. Table 1 ). All the patients were transplanted from HLA-identical sibling donors. Transplants were performed at our institution between 1995 and 2000. All the patients were HLA typed. HLA-A and B typing was performed either by serology or at the DNA level. HLA-DRB1 alleles were typed using PCR-SSO or PCR-SSP. All the tests were performed in the HLA laboratory of our facility. The control group constituted 130 healthy individuals (F/M: 61/69; age: 19-55).
Materials and methods

Patients and controls
Toxic complications
Toxicity was evaluated accordingly to the WHO standard criteria (http://www.fda.gov). The highest grade of toxic complications seen in any of the evaluated organs (mucosa, skin, liver, gut) was taken into account as the representative value of toxicity seen in an individual patient. Toxic complications grade 4 II appeared in 55 cases, 39 of which presented with severe grade III or IV toxic lesions (Table 1) .
GvHD complications
GvHD was diagnosed and graded according to the consensus conference on aGvHD diagnosis. 20 In total, 24 patients developed grade X II aGvHD complications, 10 patients had grade III or IV aGvHD (Table 1) .
TNFA and TNFB genotypes
Polymorphism within the TNFA and TNFB genes was analysed by PCR amplification followed by NcoI digestion of obtained PCR products. 21 TNFA -308 promoter polymorphism was analysed by indirect NcoI typing. The NcoI restriction site for TNFA was induced by the 5 0 -primer into the amplification product of the allele with G in position À308.
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The following primers were used for PCR amplification of 107 bp long fragment of the TNFA and 782 bp fragment of the TNFB gene:
Products of NcoI digestion were analysed electrophoretically in 2 and 4% agarose gel, for TNFB and TNFA gene fragments, respectively. Electrophoresis demonstrated the original fragment lacking the NcoI site characterised for TNFA*2 or TNFB*2 homozygous individuals, three fragments for heterozygous individuals (TNFA*1,2 or TNFB*1,2) and two fragments for homozygous individuals with allele TNFA*1 or TNFB*1, respectively.
Statistical analysis
The differences in the distributions of the TNF alleles were tested using either the w 2 test or Fisher's Exact Test (when the number of cases in any one cell of the contingency table was less than 5). Multivariate stepwise logistic regression analysis was performed using SYSTAT 8.0 software SPSS Inc. To assess the significance of two genetic factors affecting the manifestation of post-transplant complications, the method of Svejgaard and Ryder was employed. 23 Probability valueso0.05 were considered statistically significant, and those between 0.05 and 0.1 as indicative of a trend.
Results
Distribution of TNF alleles in patients and control group
Patients and control subjects presented with similar frequencies of TNFA and TNFB alleles (TNFA*1: 0.91 and 0.85; TNFA*2: 0.09 and 0.15; TNFB*1: 0.26 and 0.39; TNFB*2: 0.74 and 0.69, for patients and controls, respectively). These frequencies are also similar to those described by other studies. 6, [24] [25] [26] Manifestation of toxic lesions and aGvHD in relation to severity of conditioning regimen All the patients analysed received myeloablative treatment. A total of 42 patients were subjected to standard myeloablative procedure and 28 received more aggressive therapy (see Table 1 ).
Manifestation of severe toxic lesions is generally associated with the aggressiveness of the conditioning regimen. This is highlighted by our observation that in our group of patients, individuals on more aggressive treatment (receiving Bu Cy+(VP or Thio-Tepa)) had more frequent toxic complications than patients after standard myeloablative therapy ((Bu Cy/Bu TBI)+/ÀATG). Of the 28 patients on aggressive therapy, 96% had grades II-IV toxic lesions, while only 67% of the patients in the group on standard therapy had these complications (27/28 vs 28/42, Po0.005). Post transplant complications Toxicity grades II-IV, n (%) 55 (79%) Toxicity grade III/IV, n (%) 39 (56%) aGvHD grades II-IV, n (%) 24 (34%) aGvHD grade III/IV, n (%) 10 (14%) 
Incidence of aGvHD is related to a previous manifestation of toxic complications
Patients with grades II-IV toxic complications more frequently suffered from grade X II and more severe (III/ IV grade) aGvHD (22/24 vs 27/40, Po0.05 and 10/10 vs 39/ 54, P ¼ 0.05, for gradeXII and III-IV aGvHD, respectively). This analysis included only patients with over 30 day survival. Similar relations were observed when the manifestation of aGvHD was analysed in relation to the presence of grades III-IV toxic lesions (not shown). Thus, previous manifestation of toxic lesions associated with more frequent development of aGvHD symptoms.
Distribution of TNF genotypes in relation to toxic complications and aGvHD
Distribution of TNFA and TNFB alleles was different in the patients who presented with and without severe toxic complications (Table 2) . Patients heterozygous for one or both TNF genes studied suffered more frequently from (grades III-IV) toxic complications than those carrying the other TNF genotypes (TNFA*1,2: 9/10 vs 30/60, Po0.05; TNFB*1,2: 20/26 vs 19/44, Po0.01; TNFA*1,2 TNFB*1,2: 9/9 vs 30/61, Po0.005). In contrast to heterozygotes, patients having TNFB*2,2 and/or TNFA*1,1 less frequently presented with severe toxic lesions (TNFA*1,1 30/ 59 vs 9/11, P ¼ 0.055; TNFB*2,2: 17/39 vs 22/31, Po0.05).
TNF genotypes segregated similarly in the patient and control groups (not shown). Analysis of TNF polymorphic patterns in relation to incidence of aGvHD did not show any significant correlation. TNFA and/or TNFB genotypes were not found to affect manifestation of either grades II-IV or more severe grade III/IV aGvHD ( Table 2) .
Influence of TNF genotype on manifestation of toxic complications in relation to aggressiveness of myeloablative therapy
To assess the possible influence of the severity of the conditioning regimen on the detected relationship between TNF polymorphism and manifestation of toxic complications, the effect of TNF hetero-and homozygous genotypes was analysed separately in the groups of patients on standard and aggressive myeloablative treatment.
Among 42 patients receiving the standard conditioning regimen, 24 did not develop grade III/IV toxic lesions. In the group of cases lacking severe toxic lesions, 22 patients (92%) were carrying TNFB*2,2 and/or TNFA*1,1 genotypes. These genotypes were present in 12 patients out of 18 patients who developed severe toxic complications (22/24 vs 12/18, Po0.05). A similar tendency was observed for patients receiving aggressive treatment. All the patients lacking grade III/IV toxic complications were having TNFB*2 and/or TNFA*1 homozygous genotype (7/7 vs 18/21, ns).
Among 18 patients on standard therapy with severe toxicity, 10 patients were carrying TNFA*1,2 and/or TNFB*1,2 genotypes, while only six out of 24 patients lacking toxic lesions had these TNF genotypes (10/18 vs 6/24, Po0.05). In the patients on aggressive treatment, severe toxic lesions were seen in all the patients with TNFA*1/2 and/or TNFB*1,2 and in 11 (out of 18) patients without TNF heterozygous genotypes (10/10 vs 11/18, Po0.05).
Thus, these effects of TNFA and TNFB alleles on toxicity were independent of the severity of myeloablative conditioning regimen. Patients subjected to both standard and aggressive treatment having TNFA*1,1 and/or TNFB*2,2 were less prone to grades III-IV toxic complications, while those with TNFA*1,2 and/or TNFB*1,2 heterozygous genotypes showed severe toxic lesions more frequently. Table 2 Distribution of TNFA and TNFB genotypes in the patients having and lacking severe (grades III-IV) toxic and (grades II-IV) aGvHD complications
TNF genotype
Toxicity (grades 0-II) (n=31) Both TNFA and TNFB genotypes associate with the manifestation of grade III/IV toxic complications
As shown above, heterozygosity within both studied genes constituted risk factors for the development of grade III/IV toxic complications, while TNFB*2 and TNFA*1 homozygosity played a protective role. The lower incidence of toxic complications in TNFB*2 homozygous patients may be indirectly associated with a lower TNFa generation potential due to the presence of TNFA*1,1 genotype [15] [16] [17] and a strong association between the TNFB*2 and TNFA*1 alleles. 21 To assess the significance of two genetical factors affecting the manifestation of severe toxic complications, the method of Svejgaard and Ryder 23 was employed. Two analyses were performed. In the first analysis (Analysis I), a protective role of TNFB*2,2 and TNFA*1,1 homozygous genotypes was analysed. In the second one (Analysis II), two heterozygous genotypes, TNFA*1,2 and TNFB*1,2, were analysed as risk factors of severe toxic complications. The results are presented in Table 3 .
Analysis I concurred with our previous observations on the lower incidence of severe toxic lesions among patients carrying TNFB*2,2 and TNFA*1,1. Both these genetic features significantly prevailed in the group of patients without grades III-IV toxic lesions as compared to healthy individuals (with Po0.01 and Po0.05 for TNFA*1 and TNFB*2 homozygotes, respectively). This analysis also showed that both homozygous genotypes, TNFB*2,2 and TNFA*1,1, in a combined association fashion (Po0.01) played a protective role.
Analysis II revealed different associations of TNF heterozygous genotypes with manifestation of toxic complications. This analysis showed that TNFA*1,2 in TNFB*1,2 negative individuals (Po0.01) and TNFB*1,2 in those having TNFA*1,2 (Po0.005) influence the development of severe (grade III/IV) toxic lesions.
Logistic regression analysis of risk factors for toxicity and aGvHD
Logistic regression confirmed the independent association of recipient TNFA*1,2 genotype with severe toxic complications. In addition to this factor, aggressive myeloablative conditioning regimen and female to male transplantation setting significantly associated with the development of grade III/IV toxic lesions (Table 4 ). In multivariate analysis of aGvHD risk factors, no correlation was seen for TNF genotypes. The only variable depicted as being associated with aGvHD was recipient age (Table 4) .
Discussion
Recent studies have shown associations between the TNF polymorphic features and the incidence of post-transplant complications, aGvHD and early mortality, in the recipients of allogeneic haematopoietic stem cells. 6, 27 This was documented using short tandem repeats (STR) analysis and has not been confirmed by single nucleotide polymorphism (SNP) typing ( 6 or the present study). However, no data have been previously provided on the association between Table 3 TNFA and TNFB genotypes in relation to manifestation of grade III/IV toxic complications in the patients who suffered from haematological malignancies, recipients of allogeneic sibling stem cell transplantation
Patients with haematological malignancies
Recipients of allogeneic sibling HSCT Among 70 patients analysed, 31 showed no severe toxic lesions (mild toxicity), while the others (39 cases) presented with grade III/IV toxicity (severe toxicity). Analysis I was performed to assess the role of TNFA*1,1 (Factor A) and TNFB*2,2 (Factor B) genotypes in patients lacking severe toxic complications. In Analysis II, the influence of TNFA*,12 (Factor A) and TNFB*1,2 (Factor B) on the generation of severe toxic lesions was determined. For each comparison, the odd's ratio (OR) was calculated by Haldane's modification of Woolf's methods and the significance of its deviation was estimated by Fisher's exact test. 23 Significant associations are given in bold.
STR markers and toxicity. This is of special interest as TNFa is a proinflammatory cytokine and SNP has been shown to associate with the generation potential of this cytokine [15] [16] [17] [18] In the present study, polymorphisms of TNFa and TNFb encoding genes were analysed in patients who had suffered from haematological malignancies and were recipients of allogeneic sibling stem cell transplants. The polymorphic features of the TNFA promoter (-308) and/or TNFB intron were related to transplantation outcome. Polymorphisms within both the genes studied were found to affect the development of toxic lesions, but not aGvHD. Patients with haematological malignancies who carried TNFB*2 and/or TNFA*1 homozygous genotypes more frequently belonged to the group without severe toxic lesions (Tables  2 and 3) . Interestingly, these relations were independent of the severity of the myeloablative conditioning regimen. In addition, we showed that TNFB*2,2, together with TNFA*1,1 homozygosity in a combined associated fashion played a protective role. The positive association between the TNFA and TNFB polymorphisms and toxicity was also documented. Patients having TNFA*1,2 and/or TNFB*1,2 genotype were found to be more susceptible to development of grade III/IV toxic complications. TNFA*1,2 associated factor plays a crucial role in influencing the risk of toxic complications independent of the TNFB genotype composition. The Svajgaard and Ryder approach, employed to assess the significance of two genetical factors affecting the manifestation of severe toxic complications, showed that the generation of severe toxic lesions associates with TNFA*1,2 heterozygous genotype in patients homozygous for the TNFB alleles and with TNFB*1,2 in those having TNFA*1,2 (Table 3 ). This would imply that the relationship between the TNF heterozygosity and toxic complications may be due to the presence of TNFA*2. It is known that TNFA*2 is associated with a higher TNFa generation potential. [15] [16] [17] This may explain the increased susceptibility to toxic complications in TNFA*2-positive patients. In addition, TNFA*2 is strongly associated with TNFB*1 allele, 21 which suggests that the TNFA*2 TNFB*1 genotype contributes to the manifestation of toxic lesions.
The association of the TNFA*1,2 genotype with the development of severe toxic lesion was proved by multivariate logistic regression modelling, where, in addition to TNF genotypes, variables such as age of the recipient, gender relation and chemotherapy were included. In this analysis, female to male transplantation and aggressive myeloablative treatment were also found to be associated with severe toxicity.
However, we have not found any significant relationship between TNFA promoter (-308) and/or TNFB intron polymorphism in relation to aGvHD incidence. Similarly, Middleton et al 6 reported the lack of an association between TNFA polymorphism in -308 position and the manifestation of aGvHD. However, in the same study, they documented an association of severe (grade III/IV) aGvHD with the presence of the d3 homozygous allele in the recipients of HLA-matched sibling bone marrow transplants. 6 The difference in data might be due to the relation between toxicity and aGvHD, which may lead to the fact that the described correlation of the TNFd3 homozygosity and aGvHD, in fact, indirectly represents the observed association between TNF polymorphism and toxicity. Indeed, the TNFd3 STR marker is associated with enhanced TNFa secretion. 28 In conclusion, TNFA and TNFB genotypes influence the risk of conditioning-related toxic complications. 
